MS4A4A

MS4A4A is a tetraspanin-like membrane protein selectively expressed in macrophages, microglia, and mast cells that organizes receptor signaling by recruiting partners—dectin-1, FcεRI, KIT, and TREM2—into caveolin-1-enriched lipid raft microdomains, thereby coupling receptor engagement to PLCγ1 phosphorylation, store-operated Ca²⁺ entry, and downstream effector responses including degranulation, Arg1-dependent M2 polarization (via PI3K/AKT and JAK/STAT6), and phagocytosis (PMID:31263276, PMID:32240745, PMID:37507218, PMID:40349168). MS4A4A governs KIT endocytic recycling versus degradation in mast cells, redirecting KIT to the cell surface through caveolin-1-positive compartments (PMID:25717186). MS4A4A also stabilizes the paralog MS4A6A, which in turn complexes with DAP12 to suppress TREM2 protein levels; accordingly, MS4A4A degradation or loss elevates TREM2 and enhances microglial amyloid-β clearance, in part through increased MMP-9 production (PMID:41435829, PMID:40843775). In tumor immunity, MS4A4A blockade reprograms M2-polarized tumor-associated macrophages, restoring effector CD8⁺ T cell infiltration and reducing T cell exhaustion (PMID:37507218).

1. 2001 Medium

   Cloning of the MS4A gene family established MS4A4A as a four-transmembrane-domain protein within a chromosome 11q12-13 cluster, predicting a role in cell-surface signaling complexes but leaving its specific function unknown.

   Evidence cDNA cloning, northern blot, and genomic mapping in multiple cell types

   PMID:11245982 PMID:11401424 PMID:11486273

   Open questions at the time

   • No binding partners or signaling pathway identified
   • Expression restricted to tissue-level surveys without single-cell resolution
2. 2015 High

   The first mechanistic function was defined: MS4A4A routes KIT into caveolin-1-enriched endocytic recycling compartments in mast cells, preventing lysosomal degradation and compartmentalizing downstream Akt and PLCγ1 signaling.

   Evidence siRNA knockdown in primary human mast cells with endocytic trafficking assays, co-IP with caveolin-1, proliferation and migration readouts

   PMID:25717186

   Open questions at the time

   • Mechanism of caveolin-1 interaction (direct vs. indirect) not resolved
   • Whether KIT trafficking role extends beyond mast cells untested
3. 2019 High

   MS4A4A was shown to be a general lipid raft organizer for innate immune receptors: it recruits dectin-1 into lipid rafts on macrophages and separately colocalizes with TREM2, establishing two distinct receptor partnerships with different immunological consequences—antifungal/antimetastatic defense and sTREM2 shedding.

   Evidence Co-IP and lipid raft fractionation in macrophages; Ms4a4a KO mice challenged with tumor metastasis or dectin-1 ligands; overexpression/knockdown modulating sTREM2 in human macrophages

   PMID:31263276 PMID:31413141

   Open questions at the time

   • Whether dectin-1 and TREM2 compete for MS4A4A binding unknown
   • Structural basis of MS4A4A–receptor interactions undefined
   • sTREM2 shedding enzyme identity in this context not established
4. 2020 High

   MS4A4A was found to selectively potentiate FcεRI signaling—but not MrgprX2—by facilitating PLCγ1 phosphorylation and Orai1-mediated store-operated Ca²⁺ entry, and was placed in the IL-4/Arg1 M2 polarization axis in allergic lung inflammation.

   Evidence siRNA in human mast cells with Ca²⁺ flux, degranulation, and lipid raft assays; Ms4a4a KO mice in house dust mite allergy model with Arg1 expression analysis

   PMID:32240745 PMID:32589266

   Open questions at the time

   • How MS4A4A discriminates FcεRI from MrgprX2 at the molecular level is unclear
   • Direct mechanism linking MS4A4A to Arg1 transcription not defined
5. 2023 High

   MS4A4A was identified as a driver of M2 tumor-associated macrophage polarization through PI3K/AKT and JAK/STAT6, and its blockade reshaped the tumor immune microenvironment by reducing exhausted T cells and increasing effector CD8⁺ T cells.

   Evidence RNA-seq, western blot for PI3K/AKT and JAK/STAT6, antibody blockade and genetic inhibition in subcutaneous and orthotopic mouse tumor models with mass cytometry

   PMID:37507218

   Open questions at the time

   • Whether MS4A4A directly activates PI3K or acts via an upstream receptor not resolved
   • Therapeutic window and specificity of anti-MS4A4A antibodies in vivo not fully characterized
6. 2025 High

   A three-part mechanism was delineated: MS4A4A stabilizes MS4A6A, which forms a complex with DAP12 to suppress TREM2; MS4A4A loss or degradation therefore elevates TREM2 and enhances Aβ clearance, with MMP-9 as an additional effector for Aβ degradation, while MS4A4A's cytosolic domain anchors to the cytoskeleton to support phagocytic cup formation and Ca²⁺-dependent engulfment.

   Evidence CRISPR KO/OE in macrophages and human microglia, MS4A4A-degrading antibodies in NHP and xenotransplantation amyloid models, co-IP of MS4A6A–DAP12, 5xFAD Ms4a4a KO with in vivo microdialysis, MMP-9 ELISA in mouse and human CSF, cytoskeletal interaction studies, LNP-Il4 rescue

   PMID:40349168 PMID:40843775 PMID:41435829

   Open questions at the time

   • Whether MS4A4A–MS4A6A interaction is direct or mediated by lipid raft proximity not resolved
   • Cytoskeletal binding domain within MS4A4A not mapped
   • Relative contribution of MMP-9 versus TREM2 elevation to Aβ clearance in humans unknown
7. 2025 Medium

   MS4A4A was linked to corticosteroid resistance in macrophages: CS treatment induces MS4A4A, and Ms4a4a deletion enhances the therapeutic response to corticosteroids in experimental arthritis, revealing a pharmacologically relevant immunomodulatory axis.

   Evidence RNA-seq and IHC in CS-treated human and murine macrophages; Ms4a4a KO in experimental arthritis with CS treatment

   PMID:40924449

   Open questions at the time

   • Molecular mechanism by which MS4A4A counteracts corticosteroid action not defined
   • Whether this extends to other inflammatory diseases unknown

• Key unresolved questions include the structural basis of MS4A4A's interactions with its diverse receptor partners, the identity of the sheddase responsible for MS4A4A-dependent sTREM2 release, and whether the opposing TREM2 regulatory modes (lipid raft colocalization promoting sTREM2 shedding versus MS4A6A–DAP12-mediated TREM2 suppression) operate simultaneously or in distinct cell states.
• No high-resolution structural data for MS4A4A or its complexes
• Sheddase identity for sTREM2 in the MS4A4A context unknown
• Context-dependent switching between pro-TREM2 and anti-TREM2 functions not experimentally dissected